The Swedish-developed drug lecanemab, which was approved in the EU last autumn, is marketed under the name Leqembi.
Healthcare has been awaiting the decision from the NT Council, a collaborative body that decides whether new drug treatments should be introduced in the country.
Now the council advises the regions against offering Leqembi to patients.
The reason, according to the NT Council, is that the treatment's effect is not considered large enough for the price requested by the manufacturer. The cost of the drug for one year of treatment per patient is approximately SEK 380,000. Negotiations with the company have been conducted but have not yielded sufficient results.
There is also a lack of data on the long-term effects of the drug, according to the council.
